

# Oregon Alcohol and Drug Policy Commission

## HEALTH AND SAFETY INTERVENTIONS AGENDA



May 26, 2026, 9:30 AM – 11:00 AM

### **ZOOM Meeting link:**

<https://www.zoomgov.com/j/1601262995?pwd=Vjp7L48f2kuUbvs2TFYM44xPyd40QI.1> Meeting ID:

Meeting ID: 160 126 2995

Passcode: 680443

Dial by your location

- +1 669 254 5252 US (San Jose)
- +1 646 828 7666 US (New York)

Meeting ID: 160 126 2995

Find your local number: <https://www.zoomgov.com/u/adMCsSH7PU>

### **SCHEDULE**

9:30 – 9:35	Welcome and Organizational Business	Chair Andoniadis & Ashley Olsen
9:35 – 9:50	Expired Naloxone: National Context	Dr. Stader, The Naloxone Project
9:50- 10:00	Directors Updates	Director Dolph
10:00-10:30	Naloxone: Barriers and Solutions	Chair Andoniadis & Mara Sargent

10:30-10:55	Expired Naloxone: Oregon Context	Dr. Sarah Present, Clackamas County
10:55 – 11:00	Public Comment and Closing	Chair Andoniadis

## ADDITIONAL INFORMATION

Note: The Committee may choose to take agenda items out of order, pull, defer or shorten presentation time of agenda item(s) to accommodate unscheduled business needs. Anyone wishing to be present for an item should arrive when the meeting begins to avoid missing an item of interest

The meeting location is accessible to persons with disabilities. A request for an interpreter for the hearing impaired or for other accommodations for persons with disabilities should be made at least 48 hours before the meeting to: Ashley Olsen [ashley.Olsen@oha.oregon.gov](mailto:ashley.Olsen@oha.oregon.gov)

### 4.28.2026 ADPC HEALTH AND SAFETY INTERVENTIONS SUBCOMMITTEE RECAP NOTES:

## Organizational Business

---

**Members Present:** Stacie Andoniadis (Chair), Blue Valentine, Mariah Wright, Eric Swakhammer, Haven Wheelock, Naomi Hunsaker, Jenna Nevills, Adam Caba, Scott Jones, Amy Zamudio, Seraphina Pinsky, Crescencia Witherspoon

The meeting was called to order at 9:32 AM. Roll call was conducted and quorum was established.

## Director's Updates

Presented by Director Dolph

- **ADPC:**
  - The Commission reviewed the first quarterly update on the 2026–2030 Comprehensive Plan. Next month, the Commission will discuss how to provide clearer program level guidance to agencies seeking alignment with the plan.
  - **Next meeting: May 11, 2026**
  
- **Recovery Committee:**

- The Recovery Committee is finalizing a definition for Recovery Community Centers and preparing for a provider summit. The committee is also working with OHA on defining “recovery spaces,” a priority identified by the Youth Addiction Alliance.
- **Next meeting: May 21, 2026**
- **Treatment Committee:**
  - Treatment will begin work on provider surveys and landscape assessments.
  - **Next meeting: May 13, 2026**
- **Prevention Committee:**
  - Prevention continues their work on HB 3321 primary prevention assessment and scoping a Prevention Center of Excellence.
  - **Next meeting: May 27, 2026**
- **Federal “Dear Colleague” Letters:**
  - Update provided on recent federal guidance related to harm reduction supplies and medications for opioid use disorder. OHA is seeking clarification on this guidance and how it overlaps with current state law.

## Bylaws Approval

**Presented by Chair Andoniadis & Mara Sargent**

The committee reviewed proposed updates to the Health & Safety Committee bylaws, including:

- Adding a co-chair option
- Aligning attendance expectations with full Commission bylaws
- Updating committee name references
- Revising introductory language to reflect scope and remove outdated phrasing
- Adding “coercion” to the list of practices the committee seeks to avoid

### **ACTION ITEM:**

A fist to- -five vote was conducted; all members voted **3 or higher**, consensus reached.

**Revised bylaws were approved.**

## MMCAP Presentation and Naloxone Conversation

**Presented by Kim Hankins, Senior Health Care Consultant at MMCAP**

**Background:** MMCAP Infuse is a national cooperative group purchasing organization (GPO) that supports government facilities providing healthcare and pharmacy services.

Kim Hankins provided an overview of MMCAP Infuse, the State of Minnesota - operated GPO that offers free, voluntary membership and access to discounted pharmaceuticals and medical supplies, including several purchasing pathways for naloxone.

The presentation outlined both indirect purchasing options - through pharmacy wholesalers and medical supply vendors - and direct manufacturer agreements, which can provide additional discounts and enhanced data reporting.

ADPC staff shared early findings from the statewide naloxone financial analysis, noting that naloxone spending has been separated from other harm reduction expenditures to better understand agency level investments. The committee discussed the importance of coordinated purchasing and long-term access and agreed to keep naloxone as a standing agenda item as this work continues.

## **Public Comment**

**Presented by Chair Andoniadis**

---

No public comment was submitted.

## **ADJOURNMENT**

Meeting adjourned at 11:00 AM.